ALX ONCOLOGY HOLDINGS INC Purchase Obligation, to be Paid, Year Four and Five
ALX ONCOLOGY HOLDINGS INC (ALXO) had Purchase Obligation, to be Paid, Year Four and Five of $50.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInFourthAndFifthYear · last filed 2024-11-07
- 2024-09-30: Purchase Obligation, to be Paid, Year Four and Five $50.00K.
- 2024-06-30: Purchase Obligation, to be Paid, Year Four and Five $50.00K.
- 2024-03-31: Purchase Obligation, to be Paid, Year Four and Five $17.00K.
- 2023-09-30: Purchase Obligation, to be Paid, Year Four and Five $56.00K.
| Period end | Purchase Obligation, to be Paid, Year Four and Five |
|---|---|
| 2024-09-30 | $50.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $50.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $17.00K 10-Q · filed 2024-05-09 |
| 2023-09-30 | $56.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $33.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $30.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $40.00K 10-K · filed 2023-03-09 |
| 2021-12-31 | $83.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |